Enterprise Value

1.811B

Cash

630.8M

Avg Qtr Burn

-70.98M

Short % of Float

116.15%

Insider Ownership

0.00%

Institutional Own.

7.50%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Tremfya (guselkumab) (IL-23) Details
Psoriatic arthritis, Plaque psoriasis

Approved

Quarterly sales

Monjuvi (Tafasitamab) (CD19) Details
B-cell malignancies, Diffuse large B cell lymphoma, Chronic lymphocytic leukemia, Non-Hodgkin lymphoma, Cancer

Approved

Quarterly sales

Tafasitamab (CD19) Details
Cancer, B-cell malignancies, B-cell lymphoma, Diffuse large B cell lymphoma

Big Mover™

Susp. Mover™

Phase 3

Data readout

Tafasitamab (CD19) Details
B-cell malignancies, Cancer, Follicular lymphoma, Marginal zone lymphoma

Phase 3

Data readout

Pelabresib (CPI-0610) + ruxolitinib Details
Myelofibrosis, Cancer, Bone marrow cancer

Phase 3

Data readout

Gantenerumab Details
Alzheimer's disease

Phase 3

Update

Phase 2

Update